Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neuroendocrine Tumors × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 7 Ovarian Neoplasms 5 Neoplasm Metastasis 4 Advanced Solid Tumors 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Sarcoma, Ewing 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neuroendocrine Tumors 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Mesothelioma 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1

Interventions

Everolimus 8 lutetium Lu 177 dotatate 5 Magnetic Resonance Spectroscopy 5 pasireotide 3 Specimen Handling 3 Fluorodeoxyglucose F18 3 (177)Lu-DOTA-EB-TATE 3 olaparib 2 amino-acid, glucose, and electrolyte solution 2 Positron Emission Tomography Computed Tomography 2 Nivolumab 2 FAPI-46 2 veliparib 1 toripalimab 1 tislelizumab 1 talazoparib 1 surufatinib 1 peposertib 1 pembrolizumab 1 pelcitoclax 1 fosbretabulin 1 fludarabine phosphate 1 exemestane 1 decitabine and cedazuridine drug combination 1 dactolisib 1 cabozantinib 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1 Temozolomide 1 Sirtuins 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡